Metabolic Solutions’ improves on TZD safety
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Metabolic Solutions Development Company reports preliminary Phase IIa data showing its lead compound, MSDC-0160, improves insulin sensitivity and lowers blood glucose levels in humans without the side effects of current therapies when taken over a 28-day period. The firm says MSDC-0160, a PPAR-sparing thiazolidinedione (TZD) is similar to Lilly's TZD Actos (pioglitazone) in that it lowers circulation of fatty acids and increases HDL cholesterol, but dissimilar from Actos in that is does not decrease the levels of circulating blood cells or cause weight gain. Delivering a similar drug that would avoid the safety concerns with the broad TZDs, including the cardiovascular safety issues with GSK's Avandia (rosiglitazone), could be a significant market opportunity. The company will gather additional safety and expanded efficacy data in a 90-day Phase IIb study planned for late 2009. The firm also plans to submit an IND for a second-generation compound by the end of 2009. MSDC President Jerry Colca participated in the early development of pioglitazone while working at Upjohn
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.